Chapter 4 154 Figure S2. Predictive accuracy of PDCD1 gene expression. (A) PDCD1 scores in pretreatment samples from patients with disease control at 12 months (DC 12m) (n=12) and patients with progressive disease (PD) (n=46) in the training cohort (n=58). Only patients with available PD-1T IHC and gene expression data are included. The dashed line indicates a cut-off score of 0.20. Medians, interquartile ranges and minimum/maximum shown in boxplots, *P=0.03 by Mann Whitney U-test. (B) Receiver operating characteristic (ROC) curve for predictive value of PDCD1 for DC 12m (AUC 0.71; 95% CI: 0.54-0.88) in the training cohort (n=58). (C) Same plot as in A for pretreatment samples from patients with DC 12m (n=6) and patients with PD (n=36) in the validation cohort (n=42). P=0.06 by Mann Whitney U-test. (D) ROC curve for predictive value of PDCD1 for DC 12m (AUC 0.74; 95% CI: 0.50-0.99) in the validation cohort (n=42). (E) Progression-free survival (PFS) (median 2.9 months versus 2.0 months, HR 0.74; 95% CI: 0.37-1.47, P=0.35) and (F) overall survival (OS) (median 10.6 months versus 5.6 months, HR 0.72; 95% CI: 0.34-1.50, P=0.35) of patients with PDCD1 high (score of ≥0.20) (n=28) and PDCD1 low (score of <0.20) (n=14) pretreatment samples in the validation cohort (n=42).
RkJQdWJsaXNoZXIy MTk4NDMw